The role of intravitreal anti-vascular endothelial growth factor injection in peripheral exudative hemorrhagic chorioretinopathy: A systematic review

IF 5.1 2区 医学 Q1 OPHTHALMOLOGY
Akash Gowda MBBS , Bobak Bahrami MBBS, PhD , Wilson Wong Jun Jie MD, FRCOphth , Robert Casson MBBS (Hons), M. Biostatistics, DPhil, FRANZCO , Weng Onn Chan MBChB, MPhil, FRANZCO
{"title":"The role of intravitreal anti-vascular endothelial growth factor injection in peripheral exudative hemorrhagic chorioretinopathy: A systematic review","authors":"Akash Gowda MBBS ,&nbsp;Bobak Bahrami MBBS, PhD ,&nbsp;Wilson Wong Jun Jie MD, FRCOphth ,&nbsp;Robert Casson MBBS (Hons), M. Biostatistics, DPhil, FRANZCO ,&nbsp;Weng Onn Chan MBChB, MPhil, FRANZCO","doi":"10.1016/j.survophthal.2023.10.004","DOIUrl":null,"url":null,"abstract":"<div><p>Anti‐vascular endothelial growth factor (anti-VEGF) injections have revolutionized the field of ophthalmology, and their use in a variety of retinal diseases is growing. One target disease is peripheral exudative hemorrhagic chorioretinopathy, a disease that is uncommon and poorly understood. Despite this, there are numerous studies and case reports outlining the potential role of intravitreal injection of anti-VEGF medicines to treat it. As such, an evidence-based understanding of its risk-benefit profile is vital. We performed a comprehensive search in the PubMed, Google Scholar, and Cochrane databases for published studies and case reports relating to the use of anti-VEGF injections in peripheral exudative hemorrhagic chorioretinopathy. Anti-VEGF was first used in 2010 to aid in the management of peripheral exudative hemorrhagic chorioretinopathy. Since then, it has been increasingly used to manage this disease. Other potential management strategies, including laser photocoagulation, cryotherapy, photodynamic therapy, and vitrectomy are explored and compared with anti-VEGF where possible. Anti-VEGF appears to be an effective therapy in managing peripheral exudative hemorrhagic chorioretinopathy, especially when there is an exudative threat to the macula.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625723001315/pdfft?md5=79173a0fef752cb7d5cbab3509fdf70d&pid=1-s2.0-S0039625723001315-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Survey of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0039625723001315","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Anti‐vascular endothelial growth factor (anti-VEGF) injections have revolutionized the field of ophthalmology, and their use in a variety of retinal diseases is growing. One target disease is peripheral exudative hemorrhagic chorioretinopathy, a disease that is uncommon and poorly understood. Despite this, there are numerous studies and case reports outlining the potential role of intravitreal injection of anti-VEGF medicines to treat it. As such, an evidence-based understanding of its risk-benefit profile is vital. We performed a comprehensive search in the PubMed, Google Scholar, and Cochrane databases for published studies and case reports relating to the use of anti-VEGF injections in peripheral exudative hemorrhagic chorioretinopathy. Anti-VEGF was first used in 2010 to aid in the management of peripheral exudative hemorrhagic chorioretinopathy. Since then, it has been increasingly used to manage this disease. Other potential management strategies, including laser photocoagulation, cryotherapy, photodynamic therapy, and vitrectomy are explored and compared with anti-VEGF where possible. Anti-VEGF appears to be an effective therapy in managing peripheral exudative hemorrhagic chorioretinopathy, especially when there is an exudative threat to the macula.

玻璃体内注射抗血管内皮生长因子在外周渗出性出血性脉络膜视网膜病变中的作用:一项系统综述。
抗血管内皮生长因子(Anti-VEGF)注射已经彻底改变了眼科领域,并且它们在各种视网膜疾病中的应用越来越多。一种靶向疾病是外周渗出性出血性脉络膜视网膜病变(PEHCR),这是一种罕见且知之甚少的疾病。尽管如此,仍有大量研究和病例报告概述了玻璃体内注射抗VEGF药物治疗该病的潜在作用。因此,对其风险效益状况的循证理解至关重要。我们在PubMed、Google Scholar和Cochrane数据库中进行了全面搜索,以查找已发表的关于在外周渗出性出血性脉络膜视网膜病变中使用抗VEGF注射的研究和病例报告。抗VEGF于2010年首次用于辅助治疗外周渗出性出血性脉络膜视网膜病变。从那时起,它被越来越多地用于治疗这种疾病。探索其他潜在的治疗策略,包括激光凝固、冷冻治疗、光动力治疗和玻璃体切除术,并在可能的情况下与抗VEGF进行比较。抗VEGF似乎是治疗PEHCR的有效疗法,尤其是当黄斑有渗出性威胁时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Survey of ophthalmology
Survey of ophthalmology 医学-眼科学
CiteScore
10.30
自引率
2.00%
发文量
138
审稿时长
14.8 weeks
期刊介绍: Survey of Ophthalmology is a clinically oriented review journal designed to keep ophthalmologists up to date. Comprehensive major review articles, written by experts and stringently refereed, integrate the literature on subjects selected for their clinical importance. Survey also includes feature articles, section reviews, book reviews, and abstracts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信